在非小细胞肺癌中BRAF的途径和向途径
Evgeny N Imyanitov1,2, Natalia V Mitiushkina1, Ekatherina Sh Kuligina1
1Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia.
BRAF突变驱动一些非小细胞肺癌 (NSCLC). 虽然BRAF/MEK抑制剂有利于V600突变的NSCLC,但其他BRAF突变缺乏向治疗,需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- BRAF是一种调节MAPK通路的酶.
- 在非小细胞肺癌 (NSCLCs) 中,BRAF突变驱动了2-4%的非小细胞肺癌.
- BRAF的上调与对受体氨酸激酶抑制剂 (TKI) 的耐药性有关.
研究的目的:
- 审查BRAF突变及其在NSCLC中的作用.
- 讨论BRAF突变NSCLC的治疗方法.
- 识别BRAF突变NSCLC管理中的知识差距.
主要方法:
- 在NSCLC中对BRAF突变的文献综述.
- 分析当前的治疗策略.
- 确定研究需求.
主要成果:
- BRAF/MEK抑制剂对V600突变NSCLC提供短期益处.
- 2类和3类BRAF突变 (多达三分之二的病例) 缺乏已知的治疗方法.
- 对BRAF突变NSCLC的免疫疗法需要进一步调查.
结论:
- 针对性治疗对于NSCLC中非V600 BRAF突变是有限的.
- 为了获得有效的治疗方法,包括免疫疗法,还需要进一步的研究.
- 临床研究是可行的,因为肺癌的发病率很高.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways
MAPK Signaling Cascades
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
